HuGE Literature Finder
Records 1-30
|
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
Platelets 2019 30 (2): 229-240. Xi Ziwei, Fang Fang, Wang Jiayang, AlHelal Jumana, Zhou Yujie, Liu W |
|
CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
Gene 2018 Aug . Wang Jie-Ya, Zhang Yan-Jiao, Li He, Hu Xiao-Lei, Li Mu-Peng, Song Pei-Yuan, Ma Qi-Lin, Peng Li-Ming, Chen Xiao-Pi |
|
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Drugs & aging 2018 Jun . Galeazzi Roberta, Olivieri Fabiola, Spazzafumo Liana, Rose Giuseppina, Montesanto Alberto, Giovagnetti Simona, Cecchini Sara, Malatesta Gelsomina, Di Pillo Raffaele, Antonicelli Rober |
|
Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Cardiovascular toxicology 2018 May . Mahdieh Nejat, Rabbani Ahmad, Firouzi Ata, Zahedmehr Ali, Hoseinimoghaddam Maryam, Saeidi Sedigheh, Sanati Hamidreza, Basiri Hosseinali, Noohi Feridoun, Rabbani Bahareh, Maleki Maj |
|
Gene polymorphisms in dual antiplatelet therapy and the presence of hypo-attenuated leaflet thickening after transcatheter aortic valve replacement.
Journal of thrombosis and thrombolysis 2018 Feb . Xiong Tian-Yuan, Liao Yan-Biao, Feng Yuan, Zhao Ming-Yue, Zhao Zhen-Gang, Li Yi-Jian, Liu Xiao-Jing, Chen M |
|
Integrative medicine on optimizing clopidogrel and aspirin therapy.
Chinese journal of integrative medicine 2018 Jan . Chen H |
|
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Basic & clinical pharmacology & toxicology 2017 Jan . Saydam Faruk, De?irmenci ?rfan, Birdane Alparslan, Özdemir Mahmut, Ulus Taner, Özbayer Cansu, Çolak Ertu?rul, Ata Necmi, Güne? Hasan Vey |
|
CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.
Thrombosis research 2016 Oct 147 108-114. Tang Xiao-Fang, Han Ya-Ling, Zhang Jia-Hui, Wang Jing, Yao Yi, He Chen, Xu Bo, Gao Zhan, Qiao Shu-Bin, Chen Jue, Wu Yuan, Chen Ji-Lin, Gao Run-Lin, Yang Yue-Jin, Yuan Jin-Qi |
|
Gene polymorphism of CYP2C19*2, *3 and CYP3A4*1B and early stent thrombosis: case reports and literature review.
Personalized medicine 2016 Sep 13 (5): 423-428. Kulmyrzaeva Nazgul, Tatarunas Vacis, Skipskis Vilius, Smagulova Gaziza, Seitmaganbetova Nazgul, Veikutiene Audrone, Lesauskaite Vai |
|
CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
Medicine 2016 Jun 95 (26): e4049. Choi Ik Jun, Koh Yoon-Seok, Park Mahn-Won, Her Sung Ho, Choi Yun-Seok, Park Chul-Soo, Park Hun-Jun, Kim Pum-Joon, Chung Wook-Sung, Kim Ho-Sook, Shin Jae-Gook, Seung Ki-Bae, Chang Kiy |
|
Simultaneous subacute coronary artery stent thrombosis in a carrier of two CYP2C19 loss-of function polymorphisms (*2/*3).
International journal of cardiology 2016 Jun 212 148-50. Chikata Yuichi, Iwata Hiroshi, Osborn Eric A, Fukuda Kentaro, Okai Iwao, Shiozaki Masayuki, Kimura Yuki, Inoue Kenji, Fujiwara Yasumasa, Sumiyoshi Masata |
|
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
Acta pharmacologica Sinica 2016 May . Liu Rui, Zhou Zi-Yi, Chen Yi-Bei, Li Jia-Li, Yu Wei-Bang, Chen Xin-Meng, Zhao Min, Zhao Yuan-Qi, Cai Ye-Feng, Jin Jing, Huang M |
|
Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.
Molecular biology reports 2016 Apr . Jarrar Mohammed, Behl Shalini, Manyam Ganiraju, Ganah Hany, Nazir Mohammed, Nasab Reem, Moustafa Khal |
|
Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients.
Archivos de cardiologia de Mexico 2016 Mar . Viveros Martha Eva, Areán Carlos, Gutiérrez Sergio, Vázquez Soledad, Cardiel Mario Humberto, Taboada Alejandra, Marín Gissela, Solorio Ruben, García Nall |
|
Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention.
Thrombosis research 2016 Feb 138 49-54. Komosa A, Siller-Matula J M, Lesiak M, Michalak M, Kowal J, M?czy?ski M, Siniawski A, Mularek-Kubzdela T, Wi?niewski S, Grajek |
|
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement.
Cellular and molecular biology (Noisy-le-Grand, France) 2016 62 (1): 51-5. Kirac D, Erdem A, Avcilar T, Yesilcimen K, Guney A I, Emre A, Yazici S, Terzi S, Kaspar E C, Cetin S E, Isbir |
|
Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.
The American journal of cardiology 2015 Dec . Jain Nishank, Li Xilong, Adams-Huet Beverley, Sarode Ravi, Toto Robert D, Banerjee Subhash, Hedayati S Sus |
|
Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme.
European heart journal 2015 Nov . Puymirat Etienne, Lamhaut Lionel, Bonnet Nicolas, Aissaoui Nadia, Henry Patrick, Cayla Guillaume, Cattan Simon, Steg Gabriel, Mock Laurent, Ducrocq Gregory, Goldstein Patrick, Schiele François, Bonnefoy-Cudraz Eric, Simon Tabassome, Danchin Nicol |
|
Study design and rationale for optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients (ONSIDE TEST): a prospective, open-label, randomized parallel-group multicenter trial (NCT01930773).
Kardiologia polska 2015 Sep . Ko?towski ?ukasz, Aradi Daniel, Huczek Zenon, Tomaniak Mariusz, Sibbing Dirk, Filipiak Krzysztof J, Kochman Janusz, Balsam Pawe?, Opolski Grzego |
|
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel.
Journal of thrombosis and thrombolysis 2015 Jul 40 (1): 88-96. Li Shan, Shi Yang, Wang Haijun, Zhang Wei, Liu Jianfe |
|
Association of seven thrombotic pathway gene CpG-SNPs with coronary heart disease.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2015 May 72 98-102. Ye Huadan, Zhou Annan, Hong Qingxiao, Chen Xiaoying, Xin Yanfei, Tang Linlin, Dai Dongjun, Ji Huihui, Xu Mingqing, Wang Dao Wen, Duan Shiw |
|
Genetic testing and antiplatelet treatment: Still way to go?
International journal of cardiology 2015 May 187 63-5. Oikonomou Evangelos, Papageorgiou Nikolaos, Papaioannou Spyridon, Toutouzas Konstantinos, Latsios George, Siasos Gerasimos, Tousoulis Dimitr |
|
Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Gene 2015 Mar 558 (2): 200-7. Wang Xia-Qin, Shen Chen-Lin, Wang Bang-Ning, Huang Xiao-Hui, Hu Zhang-le, Li J |
|
Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation.
International journal of cardiology 2015 Jan 179 476-83. Konishi Akihide, Shinke Toshiro, Otake Hiromasa, Nishio Ryo, Sawada Takahiro, Takaya Tomofumi, Nakagawa Masayuki, Osue Tsuyoshi, Taniguchi Yu, Iwasaki Masamichi, Kinutani Hiroto, Masaru Kuroda, Takahashi Hachidai, Terashita Daisuke, Shite Junya, Hirata Ken-ic |
|
Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Circulation journal : official journal of the Japanese Circulation Society 2015 79 (1): 85-90. Ichikawa Minoru, Takei Yoshizumi, Hamasaki Toshimitsu, Kijima Yoshiyu |
|
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
PloS one 2015 10 (7): e0132561. Wei You-Quan, Wang Dian-Gang, Yang Hao, Cao He |
|
Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis.
Pharmacogenomics 2015 16 (3): 181-9. Kupstyte Nora, Zaliunas Remigijus, Tatarunas Vacis, Skipskis Vilius, Zaliaduonyte-Peksiene Diana, Grabauskyte Ingrida, Dovidaitiene Dovile, Bumblauskas Karolis, Gustiene Olivija, Lesauskaite Vai |
|
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.
Circulation. Cardiovascular genetics 2014 Dec 7 (6): 895-902. Sorich Michael J, Rowland Andrew, McKinnon Ross A, Wiese Michael |
|
Characterization of Patients With Angioscopically-Detected In-Stent Mural Thrombi.
Circulation journal : official journal of the Japanese Circulation Society 2014 Oct . Ichikawa Minoru, Takei Yoshizumi, Hamasaki Toshimitsu, Kijima Yoshiyu |
|
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
JACC. Cardiovascular interventions 2014 Oct 7 (10): 1117-27. Palmerini Tullio, Calabrò Paolo, Piscione Federico, De Servi Stefano, Cattaneo Marco, Maffeo Diego, Toso Anna, Bartorelli Antonio, Palmieri Cataldo, De Carlo Marco, Capodanno Davide, Barozzi Chiara, Tomasi Luciana, Della Riva Diego, Mariani Andrea, Taglieri Nevio, Reggiani Letizia Bacchi, Bianchi Renatomaria, De Rosa Roberta, Mariani Matteo, Podda GianMarco, Généreux Philippe, Stone Gregg W, Angiolillo Dominick |
|
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Pharmacogenetics and genomics 2014 Oct 24 (10): 501-13. Jiménez-Varo Enrique, Cañadas-Garre Marisa, Gutiérrez-Pimentel María J, Calleja-Hernández Miguel |
|
Pharmacogenetics role in the safety of acenocoumarol therapy.
Thrombosis and haemostasis 2014 Sep 112 (3): 522-36. Jiménez-Varo E, Cañadas-Garre M, Henriques C I, Pinheiro A M, Gutiérrez-Pimentel M J, Calleja-Hernández M |
|
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Medicina clínica 2014 Jul 143 (1): 6-12. Cano Pedro, Consuegra-Sánchez Luciano, Conesa Pablo, Torres-Moreno Daniel, Jaulent Leticia, Dau Derek, Picó Francisco, Villegas Manu |
|
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
American heart journal 2014 Jul 168 (1): 16-22.e1. Bergmeijer Thomas O, Janssen Paul W A, Schipper Jurjan C, Qaderdan Khalid, Ishak Maycel, Ruitenbeek Rianne S, Asselbergs Folkert W, van 't Hof Arnoud W J, Dewilde Willem J M, Spanó Fabrizio, Herrman Jean-Paul R, Kelder Johannes C, Postma Maarten J, de Boer Anthonius, Deneer Vera H M, ten Berg Jurriën |
|
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Pharmacogenetics and genomics 2014 Apr 24 (4): 204-10. Xie Cheng, Ding Xiaoliang, Gao Jie, Wang Haipeng, Hang Yongfu, Zhang Hua, Zhang Jingjing, Jiang Bin, Miao Liy |
|
CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention.
Journal of cardiovascular pharmacology 2014 Feb 63 (2): 178-83. Zou Jian-Jun, Chen Shao-Liang, Fan Hong-Wei, Tan Jie, He Bang-Shun, Xie Hong-Gua |
|
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
PloS one 2014 9 (10): e110188. Tresukosol Damrus, Suktitipat Bhoom, Hunnangkul Saowalak, Kamkaew Ruttakarn, Poldee Saiphon, Tassaneetrithep Boonrat, Likidlilid At |
|
Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Thrombosis research 2013 Nov 132 (5): 558-64. Nishio Ryo, Shinke Toshiro, Otake Hiromasa, Nakagawa Masayuki, Inoue Takumi, Hariki Hirotoshi, Osue Tsuyoshi, Taniguchi Yu, Iwasaki Masamichi, Hiranuma Noritoshi, Konishi Akihide, Kinutani Hiroto, Kuroda Masaru, Hirata Ken-Ic |
|
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
JACC. Cardiovascular interventions 2013 Nov 6 (11): 11. Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G |
|
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Archives of cardiovascular diseases 2013 Oct 106 (10): 517-27. Mao Liu, Jian Chen, Changzhi Liu, Dan Huang, Suihua Huang, Wenyi Tang, Wei |
|
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Pharmacogenetics and genomics 2013 Oct 23 (10): 558-62. Park Mahn-Won, Her Sung Ho, Kim Ho-Sook, Choi Yun-Seok, Park Chul-Soo, Koh Yoon-Seok, Park Hun-Jun, Kim Pum-Joon, Kim Chan Joon, Jeon Doo Soo, Shin Dong Il, Seo Suk Min, Yoo Ki-Dong, Kim Dong Bin, Kim Hee Yeol, Lee Jong Min, Chung Wook-Sung, Seung Ki-Bae, Shin Jae-Gook, Chang Kiy |
|
The CYP2C19*17 variant is not independently associated with clopidogrel response.
Journal of thrombosis and haemostasis : JTH 2013 Sep 11 (9): 1640-6. Lewis J P, Stephens S H, Horenstein R B, O'Connell J R, Ryan K, Peer C J, Figg W D, Spencer S D, Pacanowski M A, Mitchell B D, Shuldiner A |
|
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
International journal of cardiology 2013 Sep 167 (6): 2882-8. Verschuren Jeffrey J W, Boden Helèn, Wessels Judith A M, van der Hoeven Bas L, Trompet Stella, Heijmans Bastiaan T, Putter Hein, Guchelaar Henk-Jan, Schalij Martin J, Jukema J Wout |
|
Efffect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention.
Clinical and experimental pharmacology & physiology 2013 Aug 40 (8): 504-9. Zou Jian-Jun, Fan Hong-Wei, Chen Shao-Liang, Tan Jie, He Bang-Shun, Xie Hong-Gua |
|
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2013 Jul 9 (3): 316-27. Liang Zhen-Yang, Han Ya-Ling, Zhang Xiao-Lin, Li Yi, Yan Cheng-Hui, Kang Ji |
|
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
European journal of clinical pharmacology 2013 Apr 69 (4): 771-7. Zou Jian-Jun, Xie Hong-Guang, Chen Shao-Liang, Tan Jie, Lin Ling, Zhao Ying-Ying, Xu Hai-Mei, Lin Song, Zhang Juan, Wang Guang- |
|
Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.
Journal of the American Heart Association 2013 Apr 2 (2): e000131. Fontana Pierre, Cattaneo Marco, Combescure Christophe, Reny Jean-L |
|
Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Chinese medical journal 2013 Mar 126 (6): 1069-75. Tang Xiao-Fang, Zhang Jia-Hui, Wang Jing, Han Ya-Ling, Xu Bo, Qiao Shu-Bin, Wu Yong-Jian, Chen Jue, Wu Yuan, Chen Ji-Lin, Gao Run-Lin, Yang Yue-Jin, Yuan Jin-Qi |
|
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Thrombosis and haemostasis 2013 Jan 109 (4): 4. Carlquist JF, Knight S, Horne BD, Huntinghouse JA, Rollo JS, Muhlestein JB, May H, Anderson JL |
|
CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
PloS one 2013 8 (3): e59344. Xie Xiang, Ma Yi-Tong, Yang Yi-Ning, Li Xiao-Mei, Ma Xiang, Fu Zhen-Yan, Zheng Ying-Ying, Chen Bang-Dang, Liu F |
|
Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
European journal of clinical pharmacology 2012 Nov . Tang XF, Wang J, Zhang JH, Meng XM, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yuan JQ, Yang YJ |
|
Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
The American journal of cardiology 2012 Aug 110 (4): 502-8. Jang Jae-Sik, Cho Kyoung-Im, Jin Han-Young, Seo Jeong-Sook, Yang Tae-Hyun, Kim Dae-Kyeong, Kim Dong-Soo, Seol Sang-Hoon, Kim Doo-Il, Kim Bo-Hyun, Park Yong Hyun, Je Hyung-Gon, Jeong Young-Hoon, Lee Seung-Wh |
|
Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel.
Circulation journal : official journal of the Japanese Circulation Society 2012 Jul . Nishio R, Shinke T, Otake H, Sawada T, Haraguchi Y, Shinohara M, Toh R, Ishida T, Nakagawa M, Nagoshi R, Kozuki A, Inoue T, Hariki H, Osue T, Taniguchi Y, Iwasaki M, Hiranuma N, Konishi A, Kinutani H, Shite J, Hirata KI |
|
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
Journal of the American College of Cardiology 2012 May 59 (22): 1928-37. Price Matthew J, Murray Sarah S, Angiolillo Dominick J, Lillie Elizabeth, Smith Erin N, Tisch Rebecca L, Schork Nicholas J, Teirstein Paul S, Topol Eric J, |
|
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Thrombosis research 2012 Apr 129 (4): 441-6. Kassimis George, Davlouros Periklis, Xanthopoulou Ioanna, Stavrou Eleana F, Athanassiadou Aglaia, Alexopoulos Dimitri |
|
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Journal of thrombosis and haemostasis : JTH 2012 Apr 10 (4): 529-42. Siller-Matula J M, Delle-Karth G, Lang I M, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma |
|
The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Biochemical pharmacology 2012 Apr 83 (7): 903-8. Namazi Soha, Kojuri Javad, Khalili Andia, Azarpira Neg |
|
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
European heart journal 2012 Mar . Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ |
|
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
Clinical pharmacology : advances and applications 2012 4 13-20. Kreutz Rolf P, Nystrom Perry, Kreutz Yvonne, Miao Jia, Desta Zeruesenay, Breall Jeffrey A, Li Lang, Chiang Chienwei, Kovacs Richard, Flockhart David A, Jin Y |
|
Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population.
PloS one 2012 7 (6): e39178. Chen Dong-Yi, Wang Chao-Yung, Wen Ming-Shien, Lee Tsong-Hai, Chu Yen, Hsieh Ming-Jer, Chang Shang-Hung, Lee Cheng-Hung, Wang Jian-Liang, Chen Chun-Chi, Lu Laing-Suei, Lee Ming-Ta, Yeh San-Jou, Lin Fun-Chiung, Hsieh I-Cha |
|
Prediction of clopidogrel low responders by a rapid CYP2C19 activity test.
Journal of atherosclerosis and thrombosis 2012 19 (2): 186-93. Tazaki Junichi, Jinnai Toshikazu, Tada Tomohisa, Kato Yoshihiro, Makiyama Takeru, Ikeda Tomoyuki, Yamane Keiichiro, Naruse Yumiko, Takahashi Kanako, Watanabe Haruyo, Kimura Takeshi, Horiuchi Hisano |
|
Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity.
Journal of thrombosis and haemostasis : JTH 2011 Dec 9 (12): 2379-85. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, Fourtounas C, Goumenos |
|
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
JAMA 2011 Dec 306 (24): 2704-14. Holmes Michael V, Perel Pablo, Shah Tina, Hingorani Aroon D, Casas Juan |
|
Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record.
Clinical pharmacology and therapeutics 2011 Dec . Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC |
|
Prevalence of CYP2C19 polymorphisms in the Lebanese population.
Molecular biology reports 2011 Nov 38 (8): 5449-52. Djaffar Jureidini Isabelle, Chamseddine Nabil, Keleshian Sose, Naoufal Rania, Zahed Laila, Hakime No |
|
Relationship between Cytochrome P450 2C19*2 Polymorphism and Stent Thrombosis following Percutaneous Coronary Intervention in Chinese Patients Receiving Clopidogrel.
The Journal of international medical research 2011 39 (5): 5. Luo Y, Zhao YT, Verdo A, Qi WG, Zhang DF, Hu B |
|
The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients.
Journal of thrombosis and haemostasis : JTH 2011 Nov . Li Y, Tang HL, Hu YF, Xie HG |
|
[Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
Zhonghua xin xue guan bing za zhi 2011 Jul 39 (7): 617-20. Tang Xiao-Fang, He Chen, Yuan Jin-Qing, Meng Xian-Min, Yang Yue-Jin, Qin Xue-Wen, Qiao Shu-Bin, Liu Hai-Bo, Wu Yong-Jian, Yao Min, Chen Jue, You Shi-Jie, Wu Yuan, Li Jian-Jun, Dai Jun, Chen Ji-Lin, Gao Run-Lin, Chen Zai-J |
|
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
European heart journal 2011 Jul 32 (13): 1605-13. Sibbing Dirk, Koch Werner, Massberg Steffen, Byrne Robert A, Mehilli Julinda, Schulz Stefanie, Mayer Katharina, Bernlochner Isabell, Schömig Albert, Kastrati Adn |
|
Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.
Heart (British Cardiac Society) 2011 Jun . Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS |
|
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.
The pharmacogenomics journal 2011 Jun 11 (3): 199-206. Sofi F, Giusti B, Marcucci R, Gori A M, Abbate R, Gensini G |
|
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Heart (British Cardiac Society) 2011 Jun . Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R |
|
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
JACC. Cardiovascular interventions 2011 Apr 4 (4): 381-91. Kim In-Suk, Jeong Young-Hoon, Park Yongwhi, Park Ki-Soo, Yun Seong-Eun, Park Jeong-Rang, Hwang Seok-Jae, Koh Eun-Ha, Kwak Choong Hwan, Hwang Jin-Yong, Kim Sunj |
|
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Molecular biology reports 2011 Mar 38 (3): 1697-702. Jin Bo, Ni Huan-Chun, Shen Wei, Li Jian, Shi Hai-Ming, Li Yo |
|
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.
BMJ (Clinical research ed.) 2011 343 d4588. Bauer Tim, Bouman Heleen J, van Werkum Jochem W, Ford Neville F, ten Berg Jurriën M, Taubert Di |
|
Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Circulation journal : official journal of the Japanese Circulation Society 2011 75 (1): 99-105. Sawada Takahiro, Shinke Toshiro, Shite Junya, Honjo Tomoyuki, Haraguchi Yoko, Nishio Ryo, Shinohara Masakazu, Toh Ryuji, Ishida Tatsuro, Kawamori Hiroyuki, Kozuki Amane, Inoue Takumi, Hariki Hirotoshi, Hirata Ken-ic |
|
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
European heart journal 2010 Dec 31 (24): 3046-53. Harmsze Ankie M, van Werkum Jochem W, Ten Berg Jurriën M, Zwart Bastiaan, Bouman Heleen J, Breet Nicoline J, van 't Hof Arnoud W J, Ruven Hendrik J T, Hackeng Christian M, Klungel Olaf H, de Boer Anthonius, Deneer Vera H |
|
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA 2010 Oct 304 (16): 1821-30. Mega Jessica L, Simon Tabassome, Collet Jean-Philippe, Anderson Jeffrey L, Antman Elliott M, Bliden Kevin, Cannon Christopher P, Danchin Nicolas, Giusti Betti, Gurbel Paul, Horne Benjamin D, Hulot Jean-Sebastian, Kastrati Adnan, Montalescot Gilles, Neumann Franz-Josef, Shen Lei, Sibbing Dirk, Steg P Gabriel, Trenk Dietmar, Wiviott Stephen D, Sabatine Marc |
|
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.
Journal of thrombosis and haemostasis : JTH 2010 Aug 8 (8): 1685-93. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, Von Beckerath N, Mehilli J, Schömig A, Schuster T, Kastrati |
|
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Journal of thrombosis and haemostasis : JTH 2010 Aug 8 (8): 1678-84. Sorich M J, Vitry A, Ward M B, Horowitz J D, McKinnon R |
|
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.
Journal of the American College of Cardiology 2010 Jul 56 (2): 134-43. Hulot Jean-Sébastien, Collet Jean-Philippe, Silvain Johanne, Pena Ana, Bellemain-Appaix Anne, Barthélémy Olivier, Cayla Guillaume, Beygui Farzin, Montalescot Gill |
|
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Circulation 2010 Feb 121 (4): 512-8. Sibbing Dirk, Koch Werner, Gebhard Daniela, Schuster Tibor, Braun Siegmund, Stegherr Julia, Morath Tanja, Schömig Albert, von Beckerath Nicolas, Kastrati Adn |
|
Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction.
Cardiology 2010 117 (2): 81-7. Ma?ek Lukasz A, Przy?uski Jakub, Spiewak Mateusz, K?opotowski Mariusz, Kostrzewa Gra?yna, Kruk Mariusz, P?oski Rafa?, Witkowski Adam, Ru?y??o Wito |
|
Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
JACC. Cardiovascular interventions 2009 Nov 2 (11): 1095-101. Gladding Patrick, White Harvey, Voss Jamie, Ormiston John, Stewart Jim, Ruygrok Peter, Bvaldivia Badi, Baak Ruth, White Catherine, Webster Ma |
|
Perioperative genomic profiles using structure-specific oligonucleotide probes.
Clinical medicine & research 2009 Sep 7 (3): 69-84. Hogan Kirk J, Burmester James K, Caldwell Michael D, Hogan Quinn H, Coursin Douglas B, Green Dawn N, Selzer Rebecca M R, Broderick Thomas P, Rusy Deborah A, Poroli Mark, Lutz Anna L, Sanders Allison M, Oldenburg Mary C, Koelbl James A, de Arruda-Indig Monika, Halsey Jennifer L, Day Stephen P, Domanico Michael |
|
Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan.
Circulation journal : official journal of the Japanese Circulation Society 2009 Jun . Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T |
|
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
European heart journal 2009 Apr 30 (8): 916-22. Sibbing Dirk, Stegherr Julia, Latz Wolfgang, Koch Werner, Mehilli Julinda, Dörrler Katharina, Morath Tanja, Schömig Albert, Kastrati Adnan, von Beckerath Nicol |
|
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
The American journal of cardiology 2009 Mar 103 (6): 806-11. Giusti Betti, Gori Anna Maria, Marcucci Rossella, Saracini Claudia, Sestini Ilaria, Paniccia Rita, Buonamici Piergiovanni, Antoniucci David, Abbate Rosanna, Gensini Gian Fran |
|
Cytochrome p-450 polymorphisms and response to clopidogrel.
The New England journal of medicine 2009 Jan 360 (4): 354-62. Mega Jessica L, Close Sandra L, Wiviott Stephen D, Shen Lei, Hockett Richard D, Brandt John T, Walker Joseph R, Antman Elliott M, Macias William, Braunwald Eugene, Sabatine Marc |
|
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Lancet (London, England) 2009 Jan 373 (9660): 309-17. Collet Jean-Philippe, Hulot Jean-Sébastien, Pena Anna, Villard Eric, Esteve Jean-Baptiste, Silvain Johanne, Payot Laurent, Brugier Delphine, Cayla Guillaume, Beygui Farzin, Bensimon Gilbert, Funck-Brentano Christian, Montalescot Gill |
|
Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.
American journal of therapeutics 0 22 (3): 222-30. Golukhova Elena Z, Ryabinina Mariya N, Bulaeva Naida I, Grigorian Marina V, Kubova Maida Ch, Serebruany Victor |
|
CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.
Indian heart journal 0 66 (1): 16-24. Shetkar Sudhir S, Ramakrishnan Sivasubramanian, Seth Sandeep, Chandna Puneet, Verma Sunil K, Bhargava Balram, Bahl Vinay |
- Page last reviewed:Mar 16, 2019
- Page last updated:Aug 05, 2020
- Content source: